We are here to break the isolation so often felt by those with these rare diseases, and we would be delighted to welcome you into our 'family'.
The aim of our website is to direct you as quickly as possible to our support services and to information you can trust on multiple endocrine neoplasia (MEN) types 1, 2, and 3, medullary thyroid cancer (MTC), familial medullary thyroid cancer (FMTC), adrenal gland tumours (phaeochromocytomas), parathyroid hyperplasia, paragangliomas, familial isolated pituitary adenoma (FIPA) and succinate dehydrogenase (SDH) disorders.
AMEND's latest newsletter (Issue 49) is now available to registered members to view and download on this site. Please remember to log in! Registration is free, so click here to become a member of AMEND and to access the latest newsletter. Hear about our 2015 Summer Intern's experience, our 2015 Research Awards totalling £50,000, and much, much more.
Four research projects totaling £50,000 will be funded by AMEND this year.
Thanks to some exceptional fundraising by members and supporters during 2014, a special one-off fund of £40,000 was available specifically for research into medullary thyroid cancer (MTC), the most common cause of death in MEN2. MTC also occurs alone and independently of MEN. Winners this year were Professor Neil McDonald (London), Professor Chris McCabe (Birmingham) and Laura Moss (Cardiff).
As usual, the annual award of £10,000 was available for projects to do with MEN as a whole. This year's winner was Dr Paul Newey (Dundee).
AMEND is delighted to be able to fund such a range of valuable research opportunities this year.